664 related articles for article (PubMed ID: 25935097)
21. The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma.
Dummer R; Guminski A; Gutzmer R; Dirix L; Lewis KD; Combemale P; Herd RM; Kaatz M; Loquai C; Stratigos AJ; Schulze HJ; Plummer R; Gogov S; Pallaud C; Yi T; Mone M; Chang AL; Cornélis F; Kudchadkar R; Trefzer U; Lear JT; Sellami D; Migden MR
J Am Acad Dermatol; 2016 Jul; 75(1):113-125.e5. PubMed ID: 27067394
[TBL] [Abstract][Full Text] [Related]
22. Vismodegib: a guide to its use in locally advanced or metastatic basal cell carcinoma.
Lyseng-Williamson KA; Keating GM
Am J Clin Dermatol; 2013 Feb; 14(1):61-4. PubMed ID: 23329081
[TBL] [Abstract][Full Text] [Related]
23. Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma.
Lacouture ME; Dréno B; Ascierto PA; Dummer R; Basset-Seguin N; Fife K; Ernst S; Licitra L; Neves RI; Peris K; Puig S; Sokolof J; Sekulic A; Hauschild A; Kunstfeld R
Oncologist; 2016 Oct; 21(10):1218-1229. PubMed ID: 27511905
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of vismodegib in advanced basal-cell carcinoma.
Sekulic A; Migden MR; Oro AE; Dirix L; Lewis KD; Hainsworth JD; Solomon JA; Yoo S; Arron ST; Friedlander PA; Marmur E; Rudin CM; Chang AL; Low JA; Mackey HM; Yauch RL; Graham RA; Reddy JC; Hauschild A
N Engl J Med; 2012 Jun; 366(23):2171-9. PubMed ID: 22670903
[TBL] [Abstract][Full Text] [Related]
25. Targeted therapy for orbital and periocular basal cell carcinoma and squamous cell carcinoma.
Yin VT; Pfeiffer ML; Esmaeli B
Ophthalmic Plast Reconstr Surg; 2013; 29(2):87-92. PubMed ID: 23446297
[TBL] [Abstract][Full Text] [Related]
26. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome.
Tang JY; Mackay-Wiggan JM; Aszterbaum M; Yauch RL; Lindgren J; Chang K; Coppola C; Chanana AM; Marji J; Bickers DR; Epstein EH
N Engl J Med; 2012 Jun; 366(23):2180-8. PubMed ID: 22670904
[TBL] [Abstract][Full Text] [Related]
27. [Vismodegib in metastasized basal cell carcinoma].
Reinders MG; Dirix L; Mosterd K; van Doorn R
Ned Tijdschr Geneeskd; 2013; 157(12):A6011. PubMed ID: 23515044
[TBL] [Abstract][Full Text] [Related]
28. Exploring vismodegib: A non-surgical breakthrough in the management of advanced periocular basal cell carcinoma.
Lavasidis G; Tzamalis A; Tsinopoulos I; Ziakas N
Cancer Treat Res Commun; 2024; 39():100796. PubMed ID: 38367414
[TBL] [Abstract][Full Text] [Related]
29. Oral Hedgehog Pathway Inhibition as a Means for Ocular Salvage in Locally Advanced Intraorbital Basal Cell Carcinoma.
Mathis J; Doerr T; Lin E; Ibrahim SF
Dermatol Surg; 2019 Jan; 45(1):17-25. PubMed ID: 30586344
[TBL] [Abstract][Full Text] [Related]
30. Emergence of chemoresistance in a metastatic basal cell carcinoma patient after complete response to hedgehog pathway inhibitor vismodegib (GDC-0449).
Meani RE; Lim SW; Chang AL; Kelly JW
Australas J Dermatol; 2014 Aug; 55(3):218-21. PubMed ID: 25117162
[TBL] [Abstract][Full Text] [Related]
31. An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma.
Ally MS; Aasi S; Wysong A; Teng C; Anderson E; Bailey-Healy I; Oro A; Kim J; Chang AL; Tang JY
J Am Acad Dermatol; 2014 Nov; 71(5):904-911.e1. PubMed ID: 24929884
[TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy of vismodegib in patients aged ≥65 years with advanced basal cell carcinoma.
Chang AL; Lewis KD; Arron ST; Migden MR; Solomon JA; Yoo S; Day BM; McKenna EF; Sekulic A
Oncotarget; 2016 Nov; 7(46):76118-76124. PubMed ID: 27764798
[TBL] [Abstract][Full Text] [Related]
33. Two different scenarios of advanced basal cell carcinomas during the use of vismodegib: Cases of oral administration and administration directly to the stomach.
Rodríguez-Cerdeira C; Muñoz-Garzón V; González-Cespón JL
Drug Discov Ther; 2019; 13(2):122-127. PubMed ID: 31080204
[TBL] [Abstract][Full Text] [Related]
34. Comparison of daily dosing versus Monday through Friday dosing of vismodegib for locally advanced basal cell carcinoma and basal cell nevus syndrome: A retrospective case series.
Wong C; Poblete-Lopez C; Vidimos A
J Am Acad Dermatol; 2020 Jun; 82(6):1539-1542. PubMed ID: 32092372
[No Abstract] [Full Text] [Related]
35. Efficacy and safety profile of vismodegib in a real-world setting cohort of patients with advanced basal cell carcinoma in Argentina.
Cozzani R; Del Aguila R; Carrizo M; Sanchez S; Gonzalez A;
Int J Dermatol; 2020 May; 59(5):627-632. PubMed ID: 32034775
[TBL] [Abstract][Full Text] [Related]
36. Experience With Vismodegib in the Treatment of Advanced Basal Cell Carcinoma at a Cancer Center.
Bernia E; Llombart B; Serra-Guillén C; Bancalari B; Nagore E; Requena C; Calomarde L; Diago A; Lavernia J; Traves V; Guillén C; Sanmartín O
Actas Dermosifiliogr (Engl Ed); 2018 Nov; 109(9):813-820. PubMed ID: 30055751
[TBL] [Abstract][Full Text] [Related]
37. Efficacy, rate of tumor response, and safety of a short course (12-24 weeks) of oral vismodegib in various histologic subtypes (infiltrative, nodular, and superficial) of high-risk or locally advanced basal cell carcinoma, in an open-label, prospective case series clinical trial.
Fosko SW; Chu MB; Armbrecht E; Galperin T; Potts GA; Mattox A; Kurta A; Polito K; Slutsky JB; Burkemper NM; Hurley MY
J Am Acad Dermatol; 2020 Apr; 82(4):946-954. PubMed ID: 31836564
[TBL] [Abstract][Full Text] [Related]
38. Systemic treatments for basal cell carcinoma (BCC): the advent of dermato-oncology in BCC.
Ali FR; Lear JT
Br J Dermatol; 2013 Jul; 169(1):53-7. PubMed ID: 23488543
[TBL] [Abstract][Full Text] [Related]
39. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.
Sekulic A; Migden MR; Basset-Seguin N; Garbe C; Gesierich A; Lao CD; Miller C; Mortier L; Murrell DF; Hamid O; Quevedo JF; Hou J; McKenna E; Dimier N; Williams S; Schadendorf D; Hauschild A;
BMC Cancer; 2017 May; 17(1):332. PubMed ID: 28511673
[TBL] [Abstract][Full Text] [Related]
40. Discovery and preclinical development of vismodegib.
Gould SE; Low JA; Marsters JC; Robarge K; Rubin LL; de Sauvage FJ; Sutherlin DP; Wong H; Yauch RL
Expert Opin Drug Discov; 2014 Aug; 9(8):969-84. PubMed ID: 24857041
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
